...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?
【24h】

Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?

机译：替米沙坦：保护不同人群的不同血管紧张素II受体阻滞剂？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET?) showed that the angiotensin II receptor blocker (ARB) telmisartan was as protective as the reference-standard ramipril in a broad cross-section of patients at increased cardiovascular risk, but was better tolerated. Telmisartan has a unique profile among ARBs, with a high affinity for the angiotensin II type 1 receptor, a long duration of receptor binding, a high lipophilicity and a long plasma half life. This leads to sustained and powerful blood pressure lowering when compared with the first marketed ARBs, such as losartan and valsartan. Some pharmacological properties of telmisartan clearly distinguish it from other members of the ARB class and may contribute to the clinical effects seen with telmisartan. A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients.
机译：正在进行中的替米沙坦单独治疗与雷米普利全球终点试验（ONTARGET？）的结合表明，在心血管风险增加的广大患者中，血管紧张素II受体阻滞剂（ARB）替米沙坦具有与参考标准雷米普利同等的保护作用，但耐受性更好。替米沙坦在ARB中具有独特的特征，对1型血管紧张素II受体具有高亲和力，受体结合时间长，亲脂性高，血浆半衰期长。与氯沙坦和缬沙坦等首批上市的ARB相比，这导致血压持续而有力地降低。替米沙坦的某些药理特性清楚地将其与ARB类的其他成员区分开来，并可能有助于替米沙坦的临床疗效。无法假定ARB的类别效应。迄今为止，替米沙坦是唯一被证明可以降低高危心血管患者心血管疾病风险的ARB。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号